GENE ONLINE|News &
Opinion
Blog

2018-05-29| ChinaFundingStartups

Beijing AI+Blockchain Pharma Startup Received Millions of USD Pre-A Financing

by GeneOnline
Share To

Deep Intelligent Pharma (DIP), a company integrating artificial intelligent (AI) technology with pharmaceutical development, received millions of US dollar from ZhenFund, a Beijing-based seed capital, in its pre-A round financing last December. This message was released by a spokesperson at DIP on May 24.

By Joanne Shih

DIP is a technology start-up launched in Beijing in October 2017, applying AI and blockchain technologies to facilitate drug discovery, development, and medical regulatory affairs. Established in China, the company sets its headquarters in Beijing, but branches in both China and the US with offices in Shanghai, Shenyang, Boston, and Silicon Vally. Currently, DIP has over 50 full-time employees.

The company has launched around ten products and collaborated with several Chinese, Asia Pacific, and global pharmaceutical companies since its establishment. Aiming to empower advancement in medical and pharmaceutical industries, DIP has six major product lines which respectively are: 1) Intelligent Pharmacovigilance, 2) A.I.M AI IN MEDICAL, 3) A Blockchain-based, Patient-research Ecosystem, 4) Intelligent Medical Writing, 5) Medical Translations, and 6) Intelligent Regulatory Affairs Solution. Among these products, AI and blockchain play a pivot role in creating new platforms for medical and clinical research and in allowing medical data to be used appropriately.

Emma Yin, Investment Vice President at ZhenFund, said, “DIP is formed by a talented pool from international pharmaceutical giants including Johnson & Johnson, Pfizer, Eli Lilly, Novartis, as well as AI algorithmists from Alibaba and experts in natural language processing. It is a true combination of AI technology and drug R&D. Therefore, DIP has the potential to develop viable solutions and meet demands in pharmaceutical market.”

Reference

https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0p99g009btfcwvn

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
R&D
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
AI-Driven Breakthroughs in Drug Discovery and Treatment Optimization
2024-04-02
LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top